PD-L1-话题@MedSci

#PD-L1#

309篇内容 | 6146人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2092179, encodeId=5e3920921e957, content=Carolyn Bertozzi 实验室利用<a href='/topic/show?id=dd651048945d' target=_blank style='color:#2F92EE;'>#生物正交反应#</a>来追踪生物体内的分子间相互作用，以及它们对疾病的作用，并对细胞、组织、器官进行标记和成像。他们还发现，肿瘤细胞表面的<a href='/topic/show?id=e1a3104895c2' target=_blank style='color:#2F92EE;'>#聚糖#</a>可以保护<a href='/topic/show?id=aa0582e6946' target=_blank style='color:#2F92EE;'>#肿瘤#</a>细胞免受免疫系统的杀伤作用。基于这些发现，他们开发了一种全新的抗癌药物类型，将分解聚糖的<a href='/topic/show?id=0698104896f1' target=_blank style='color:#2F92EE;'><a href='/topic/show?id=0698104896f1' target=_blank style='color:#2F92EE;'>#唾液酸酶#</a></a>与肿瘤特异性抗体结合，增强<a href='/topic/show?id=d8dbe130197' target=_blank style='color:#2F92EE;'>#癌症#</a>治疗效果。基于上述发现，Carolyn Bertozzi 于2015年创立了一家名为 Palleon Pharmaceuticals 的生物技术公司，致力于开发糖介导的免疫调节治疗癌症和<a href='/topic/show?id=56bf6e024d4' target=_blank style='color:#2F92EE;'>#炎症性疾病#</a>，例如将<a href='/topic/show?id=0698104896f1' target=_blank style='color:#2F92EE;'><a href='/topic/show?id=0698104896f1' target=_blank style='color:#2F92EE;'>#唾液酸酶#</a></a>与<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a> 或 <a href='/topic/show?id=e3818e1893' target=_blank style='color:#2F92EE;'>#HER2#</a> 抗体形成<a href='/topic/show?id=00d88886e5e' target=_blank style='color:#2F92EE;'>#融合蛋白#</a>，实现双管齐下的抗癌效果。目前该公司已完成约1.5亿美元融资，其中靶向肿瘤细胞和免疫细胞上的<a href='/topic/show?id=1bd710489eaa' target=_blank style='color:#2F92EE;'>#免疫抑制性唾液聚糖#</a>的双功能唾液酸酶融合蛋白药物 E-602 已处于1/2期临床研究阶段。, objectTitle=2022年诺贝尔化学奖得主：用化学技术颠覆癌症治疗，创立公司获数亿美元融资，已开展临床试验, objectType=article, longId=741869, objectId=805de418690c, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/images/20220927/b125dbdb0160420081d14e819732e717.jpg, objectUrl=/article/show_article.do?id=805de418690c, replyNumber=0, likeNumber=200, createdTime=2022-10-07, rootId=0, userName=lifestar, userId=aa0e14, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=805de418690c, moduleTitle=2022年诺贝尔化学奖得主：用化学技术颠覆癌症治疗，创立公司获数亿美元融资，已开展临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=805de418690c)], followStatus=false, userIsMember=false, type=1, lengthMark=1), GetTopicListResponse(id=2089208, encodeId=df7f208920838, content=与安慰剂相比，<a href='/topic/show?id=1c4e65265d5' target=_blank style='color:#2F92EE;'>#派姆单抗#</a><a href='/topic/show?id=89a810615bb' target=_blank style='color:#2F92EE;'>#K药#</a>显著延长了完全切除的IB-IIIA期<a href='/topic/show?id=2493130e1a1' target=_blank style='color:#2F92EE;'>#NSCLC#</a>患者的无病生存期，无论<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>表达水平如何，而且无新的安全性问题。派姆单抗可作为完全切除后的IB-IIIA期NSCLC患者的新治疗选择。说明术后辅助也是有效的，那么如果术前做<a href='/topic/show?id=1a5a58e00ad' target=_blank style='color:#2F92EE;'>#新辅助治疗#</a>，术后再做一段时间辅助，会不会更好？？, objectTitle=Lancet Oncol：派姆单抗辅助治疗可显著延长术后IB-IIIA期NSCLC患者的生存期, objectType=article, longId=740057, objectId=aad8e40057a1, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20220919/1663595268646_2110107.JPG, objectUrl=/article/show_article.do?id=aad8e40057a1, replyNumber=0, likeNumber=161, createdTime=2022-09-20, rootId=0, userName=小小医者, userId=f63e4754896, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aad8e40057a1, moduleTitle=Lancet Oncol：派姆单抗辅助治疗可显著延长术后IB-IIIA期NSCLC患者的生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=aad8e40057a1)], followStatus=false, userIsMember=false, type=1, lengthMark=1), GetTopicListResponse(id=1255174, encodeId=4b2a12551e46d, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=JAMA Oncol：PD-L1表达水平对晚期胃食管癌患者从ICI治疗中获益的预测价值, objectType=article, longId=738658, objectId=9f99e3865805, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9f99e3865805, replyNumber=0, likeNumber=104, createdTime=2022-09-10, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9f99e3865805, moduleTitle=JAMA Oncol：PD-L1表达水平对晚期胃食管癌患者从ICI治疗中获益的预测价值, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9f99e3865805)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255173, encodeId=e0a212551e3ff, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=Science子刊：欧阳波团队揭示胆固醇调控PD-L1稳定性的分子机制, objectType=article, longId=737833, objectId=ec59e37833c2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ec59e37833c2, replyNumber=0, likeNumber=155, createdTime=2022-09-06, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ec59e37833c2, moduleTitle=Science子刊：欧阳波团队揭示胆固醇调控PD-L1稳定性的分子机制, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ec59e37833c2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255172, encodeId=13c312551e253, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=百奥赛图与TRACON共同宣布YH001（CTLA-4单抗）联合恩沃利单抗（PD-L1）一线治疗软组织肉瘤的临床试验申请获得FDA批准, objectType=article, longId=737420, objectId=555de3742013, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=555de3742013, replyNumber=0, likeNumber=131, createdTime=2022-09-01, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=555de3742013, moduleTitle=百奥赛图与TRACON共同宣布YH001（CTLA-4单抗）联合恩沃利单抗（PD-L1）一线治疗软组织肉瘤的临床试验申请获得FDA批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=555de3742013)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255171, encodeId=c45812551e121, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=PD-1耐药了就只能做化疗了？别急，继续用PD-L1疗效也很好, objectType=article, longId=736362, objectId=dcbde363627c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dcbde363627c, replyNumber=0, likeNumber=171, createdTime=2022-08-21, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dcbde363627c, moduleTitle=PD-1耐药了就只能做化疗了？别急，继续用PD-L1疗效也很好, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dcbde363627c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255170, encodeId=3b6d12551e090, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=Blood：尼洛替尼联合PD-L1阻滞可逆转CD4+T细胞耗竭预防B-ALL复发, objectType=article, longId=736337, objectId=b0e3e36337f3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b0e3e36337f3, replyNumber=0, likeNumber=102, createdTime=2022-08-21, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b0e3e36337f3, moduleTitle=Blood：尼洛替尼联合PD-L1阻滞可逆转CD4+T细胞耗竭预防B-ALL复发, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b0e3e36337f3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255169, encodeId=bc3f125516969, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=JITC：突破性进展！开发出一种有望使免疫疗法适用于所有癌症患者的小分子PD-1/PD-L1抑制剂, objectType=article, longId=736109, objectId=7fe7e3610956, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7fe7e3610956, replyNumber=0, likeNumber=102, createdTime=2022-08-19, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7fe7e3610956, moduleTitle=JITC：突破性进展！开发出一种有望使免疫疗法适用于所有癌症患者的小分子PD-1/PD-L1抑制剂, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7fe7e3610956)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255168, encodeId=6e5d125516825, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=Nat Commun：HRS磷酸化驱动PD-L1外泌体分泌并限制CD8+T细胞肿瘤浸润, objectType=article, longId=734443, objectId=eb3fe3444390, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=eb3fe3444390, replyNumber=0, likeNumber=124, createdTime=2022-08-06, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=eb3fe3444390, moduleTitle=Nat Commun：HRS磷酸化驱动PD-L1外泌体分泌并限制CD8+T细胞肿瘤浸润, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=eb3fe3444390)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255167, encodeId=ec19125516e93, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=【精彩直播】PD-L1高表达晚期NSCLC免疫治疗的选择, objectType=article, longId=733248, objectId=3970e33248b6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3970e33248b6, replyNumber=0, likeNumber=82, createdTime=2022-07-27, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3970e33248b6, moduleTitle=【精彩直播】PD-L1高表达晚期NSCLC免疫治疗的选择, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3970e33248b6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255166, encodeId=a4f11255166a0, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=Clin Cancer Res：新型PD-L1抗体TQB2450联合安罗替尼治疗晚期软组织肉瘤的效果可期！, objectType=article, longId=731131, objectId=289fe31131ee, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=289fe31131ee, replyNumber=0, likeNumber=100, createdTime=2022-07-04, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=289fe31131ee, moduleTitle=Clin Cancer Res：新型PD-L1抗体TQB2450联合安罗替尼治疗晚期软组织肉瘤的效果可期！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=289fe31131ee)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255165, encodeId=ce241255165c6, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=Journal for Immunotherapy of Cancer：罗成/党永军团队等发现L-5-羟基色氨酸可抑制PD-L1表达，发挥抗肿瘤效应, objectType=article, longId=730901, objectId=f8c7e3090132, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f8c7e3090132, replyNumber=0, likeNumber=98, createdTime=2022-07-01, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f8c7e3090132, moduleTitle=Journal for Immunotherapy of Cancer：罗成/党永军团队等发现L-5-羟基色氨酸可抑制PD-L1表达，发挥抗肿瘤效应, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f8c7e3090132)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255164, encodeId=ccc012551640b, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=后免疫时代 PD-1/PD-L1耐药应该如何解决？, objectType=article, longId=730690, objectId=3ba0e3069062, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3ba0e3069062, replyNumber=0, likeNumber=96, createdTime=2022-06-29, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3ba0e3069062, moduleTitle=后免疫时代 PD-1/PD-L1耐药应该如何解决？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3ba0e3069062)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255163, encodeId=58e3125516383, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=Clin Cancer Res：新型PD-L1抗体TQB2450联合安罗替尼治疗局部晚期/转移性软组织肉瘤, objectType=article, longId=729559, objectId=1586e2955944, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1586e2955944, replyNumber=0, likeNumber=107, createdTime=2022-06-16, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1586e2955944, moduleTitle=Clin Cancer Res：新型PD-L1抗体TQB2450联合安罗替尼治疗局部晚期/转移性软组织肉瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1586e2955944)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255162, encodeId=a8931255162a4, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=PD-1用多久？PD-1与PD-L1有何区别？一文搞清, objectType=article, longId=729218, objectId=bc80e2921850, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bc80e2921850, replyNumber=0, likeNumber=76, createdTime=2022-06-14, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bc80e2921850, moduleTitle=PD-1用多久？PD-1与PD-L1有何区别？一文搞清, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bc80e2921850)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255161, encodeId=7708125516134, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=J Clin Oncol：信迪利单抗联合安罗替尼作为二线或后线治疗PD-L1阳性复发或转移(R/M) 宫颈癌的疗效和安全性, objectType=article, longId=728373, objectId=4ee9e283734e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4ee9e283734e, replyNumber=0, likeNumber=0, createdTime=2022-06-02, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4ee9e283734e, moduleTitle=J Clin Oncol：信迪利单抗联合安罗替尼作为二线或后线治疗PD-L1阳性复发或转移(R/M) 宫颈癌的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4ee9e283734e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255160, encodeId=27e7125516042, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=2022 ASCO：PD-L1抑制剂联合EP作为一线疗法对广泛期小细胞肺癌伴有脑转移的的疗效, objectType=article, longId=728252, objectId=27bce282523d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=27bce282523d, replyNumber=0, likeNumber=114, createdTime=2022-06-01, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=27bce282523d, moduleTitle=2022 ASCO：PD-L1抑制剂联合EP作为一线疗法对广泛期小细胞肺癌伴有脑转移的的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=27bce282523d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255159, encodeId=acc8125515901, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=一表讲全！PD-1/PD-L1 免疫抑制剂使用宝典, objectType=article, longId=727591, objectId=61c0e27591d8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=61c0e27591d8, replyNumber=0, likeNumber=82, createdTime=2022-05-24, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=61c0e27591d8, moduleTitle=一表讲全！PD-1/PD-L1 免疫抑制剂使用宝典, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=61c0e27591d8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255158, encodeId=c2e5125515898, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=Lancet Oncol：Tiragolumab联合阿替利珠单抗作为一线方案治疗PD-L1阳性NSCLC, objectType=article, longId=727300, objectId=7f29e2730032, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7f29e2730032, replyNumber=0, likeNumber=77, createdTime=2022-05-20, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7f29e2730032, moduleTitle=Lancet Oncol：Tiragolumab联合阿替利珠单抗作为一线方案治疗PD-L1阳性NSCLC, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7f29e2730032)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255157, encodeId=6903125515edd, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=PD-L1 vs PD-1：同是免疫检查点，却有诸多不同, objectType=article, longId=726877, objectId=3cede2687745, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3cede2687745, replyNumber=0, likeNumber=158, createdTime=2022-05-16, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3cede2687745, moduleTitle=PD-L1 vs PD-1：同是免疫检查点，却有诸多不同, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3cede2687745)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

PD-L1

2020-05-29

lifestar (审核中...)

前往app查看评论内容

全文收起 Carolyn Bertozzi 实验室利用#生物正交反应#来追踪生物体内的分子间相互作用，以及它们对疾病的作用，并对细胞、组织、器官进行标记和成像。他们还发现，肿瘤细胞表面的#聚糖#可以保护#肿瘤#细胞免受免疫系统的杀伤作用。基于这些发现，他们开发了一种全新的抗癌药物类型，将分解聚糖的 #唾液酸酶#与肿瘤特异性抗体结合，增强#癌症#治疗效果。基于上述发现，Carolyn Bertozzi 于2015年创立了一家名为 Palleon Pharmaceuticals 的生物技术公司，致力于开发糖介导的免疫调节治疗癌症和#炎症性疾病#，例如将 #唾液酸酶#与#PD-L1# 或 #HER2# 抗体形成#融合蛋白#，实现双管齐下的抗癌效果。目前该公司已完成约1.5亿美元融资，其中靶向肿瘤细胞和免疫细胞上的#免疫抑制性唾液聚糖#的双功能唾液酸酶融合蛋白药物 E-602 已处于1/2期临床研究阶段。

2022年诺贝尔化学奖得主：用化学技术颠覆癌症治疗，创立公司获数亿美元融资，已开展临床试验

2022-10-07

小小医者 (审核中...)

前往app查看评论内容

全文收起与安慰剂相比，#派姆单抗##K药#显著延长了完全切除的IB-IIIA期#NSCLC#患者的无病生存期，无论#PD-L1#表达水平如何，而且无新的安全性问题。派姆单抗可作为完全切除后的IB-IIIA期NSCLC患者的新治疗选择。说明术后辅助也是有效的，那么如果术前做#新辅助治疗#，术后再做一段时间辅助，会不会更好？？

Lancet Oncol：派姆单抗辅助治疗可显著延长术后IB-IIIA期NSCLC患者的生存期

2022-09-20

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

JAMA Oncol：PD-L1表达水平对晚期胃食管癌患者从ICI治疗中获益的预测价值

2022-09-10

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

Science子刊：欧阳波团队揭示胆固醇调控PD-L1稳定性的分子机制

2022-09-06

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

百奥赛图与TRACON共同宣布YH001（CTLA-4单抗）联合恩沃利单抗（PD-L1）一线治疗软组织肉瘤的临床试验申请获得FDA批准

2022-09-01

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

PD-1耐药了就只能做化疗了？别急，继续用PD-L1疗效也很好

2022-08-21

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

Blood：尼洛替尼联合PD-L1阻滞可逆转CD4+T细胞耗竭预防B-ALL复发

2022-08-21

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

JITC：突破性进展！开发出一种有望使免疫疗法适用于所有癌症患者的小分子PD-1/PD-L1抑制剂

2022-08-19

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

Nat Commun：HRS磷酸化驱动PD-L1外泌体分泌并限制CD8+T细胞肿瘤浸润

2022-08-06

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

【精彩直播】PD-L1高表达晚期NSCLC免疫治疗的选择

2022-07-27

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

Clin Cancer Res：新型PD-L1抗体TQB2450联合安罗替尼治疗晚期软组织肉瘤的效果可期！

2022-07-04

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

Journal for Immunotherapy of Cancer：罗成/党永军团队等发现L-5-羟基色氨酸可抑制PD-L1表达，发挥抗肿瘤效应

2022-07-01

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

后免疫时代 PD-1/PD-L1耐药应该如何解决？

2022-06-29

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

Clin Cancer Res：新型PD-L1抗体TQB2450联合安罗替尼治疗局部晚期/转移性软组织肉瘤

2022-06-16

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

PD-1用多久？PD-1与PD-L1有何区别？一文搞清

2022-06-14

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

J Clin Oncol：信迪利单抗联合安罗替尼作为二线或后线治疗PD-L1阳性复发或转移(R/M) 宫颈癌的疗效和安全性

2022-06-02

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

2022 ASCO：PD-L1抑制剂联合EP作为一线疗法对广泛期小细胞肺癌伴有脑转移的的疗效

2022-06-01

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

一表讲全！PD-1/PD-L1 免疫抑制剂使用宝典

2022-05-24

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

Lancet Oncol：Tiragolumab联合阿替利珠单抗作为一线方案治疗PD-L1阳性NSCLC

2022-05-20

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

PD-L1 vs PD-1：同是免疫检查点，却有诸多不同

2022-05-16

科室
- - 订阅+
  - 更多科室
工具
服务